| Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. | |
| | |
MedLine Citation:
|
PMID: 20538031 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Interleukin-1 receptor antagonist (IL-1Ra) is a good indicator of disease activity in patients with systemic lupus erythematosus (SLE). Glucocorticosteroids are the most frequently used drugs in SLE. Our goal was to compare IL-1Ra activity in SLE patients with and without renal involvement and to determine the effect of different dosage of glucocorticosteroids used in 17 patients with active SLE without nephritis, 7 patients with inactive lupus nephritis (LN), and 8 patients with active LN, along with 10 healthy controls. IL-1Ra levels were measured in the serum of SLE patients by Human Luminex [100] analyzer. Both in patients with active SLE without nephritis and in patients with LN, serum levels of IL-1Ra (p<0.001) were significantly higher compared with those in the controls. IL-1Ra was significantly higher in patients with active LN than in patients with inactive LN (p = 0.028). The use of methylprednisolone was significantly higher in the active LN group compared with the inactive LN group (p = 0.013). SLE patients with higher IL-1Ra are at lower risk for developing nephritis. The higher doses of glucocorticosteroids needed in active LN could be due to steroid resistance and IL-1Ra polymorphism. Measurement of IL-1Ra levels in SLE patients could help to predict future renal involvement. |
| | |
Authors:
|
Boglarka Brugos; Emese Kiss; Csaba Dul; Wolfgang Gubisch; Gyula Szegedi; Sandor Sipka; Margit Zeher |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-06-09 |
Journal Detail:
|
Title: Human immunology Volume: 71 ISSN: 1879-1166 ISO Abbreviation: Hum. Immunol. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-27 Completed Date: 2011-01-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8010936 Medline TA: Hum Immunol Country: United States |
Other Details:
|
Languages: eng Pagination: 874-7 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
3rd Department of Internal Medicine, Division of Clinical Immunology, Medical and Health Science Center of University of Debrecen, Debrecen, Hungary. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Biological Markers / blood C-Reactive Protein / metabolism Creatinine / blood Cyclophosphamide / therapeutic use Cyclosporine / therapeutic use Female Glomerular Filtration Rate / physiology Humans Interleukin 1 Receptor Antagonist Protein / blood* Lupus Erythematosus, Systemic / blood*, diagnosis, drug therapy, physiopathology* Lupus Nephritis / blood*, diagnosis, drug therapy, physiopathology* Male Metabolic Clearance Rate / physiology Methylprednisolone / therapeutic use Middle Aged Proteinuria / urine Severity of Illness Index Young Adult beta 2-Glycoprotein I / blood |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Interleukin 1 Receptor Antagonist Protein; 0/beta 2-Glycoprotein I; 50-18-0/Cyclophosphamide; 59865-13-3/Cyclosporine; 60-27-5/Creatinine; 83-43-2/Methylprednisolone; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Balanced polymorphism in bottlenecked populations: the case of the CCR5 5' cis-regulatory region in ...
Next Document: Induction of apoptosis in human cervical carcinoma HeLa cells by polymethoxylated flavone-rich Citru...